Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore
10.1016/j.vhri.2012.03.002
Saved in:
Main Authors: | Lopes, G., Burke, T., Pellissier, J., Zhang, X.-H., Dedhiya, S., Chan, A. |
---|---|
Other Authors: | PHARMACY |
Format: | Article |
Published: |
2014
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/105676 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
by: Suthinee Ithimakin, et al.
Published: (2020) -
International radiation oncology trainee decision making in the management of radiotherapy-induced nausea and vomiting
by: Dennis, K., et al.
Published: (2016) -
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy
by: Molassiotis, A., et al.
Published: (2021) -
Symptom clusters change over time among patients with gynecological cancer receiving chemotherapy
by: Haryani, Haryani, et al.
Published: (2022) -
Clinical evaluation of once-weekly dosing of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy
by: Narin Voravud
Published: (2006)